Plunkett Research Online: Geron Corporation

GERON CORPORATION (GERN:NAS) Company Profile, Corporate Revenues, Growth, Market Size, Analysis, Business Forecasts, Market Share, Metrics, SWOT

Geron Corporation is a late-stage biopharmaceutical company currently focused on the development of a telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. Imetelstat is Geron’s sole product candidate, and is based on core expertise in telomerase and telomere biology. Telomerase i.....



Geron Corporation
Ticker: GERN
Exchange: NAS
Parent Company:
Year Established:
Employees:
Fiscal Year Ends in

Phone: 650 473-7700
Fax: 650 473-7750
Address: 149 Commonwealth Drive
Suite 2070
Menlo Park, CA 94025 United States

Types Of Business
Industry Ranks

Industry NAICS code:

Drug Discovery & Development
Telomerase Technologies
Human Stem Cell Technologies
ContactsDescription

John ScarlettCEO/Chairman of the Board/Director/President
Olivia BloomCFO/Chief Accounting Officer/Executive VP, Divisional/Treasurer
See More
Geron Corporation is a late-stage biopharmaceutical company currently focused on the development of a telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. Imetelstat is Geron’s sole product candidate, and is based on core expertise in telomerase and telomere biology. Telomerase i.....See More See More

Auditor: EY
Legal Advisor: Latham & Watkins LLP
$USD, In whole numbers,
except marked * or %
201920182017201620152014
Financials
    Revenue
    Cost of Revenue
    Gross Margin %
    R&D Expense
    Operating Income
    Operating Margin %
    SGA Expense
    Net Income
    Earnings Per Share
    Dividends
    Book Value Per Share
    Operating Cash Flow
    Capital Expenditure
    Free Cash Flow
Profitability
    EBITDA
    Return on Assets %
    Return on Equity %
    Net Margin %
    Assets Turnover
    Financial Leverage
Brands, Divisions and AffiliatesTop Salaries
Imetelstat
NameTitleSalary (US$)Bonus (US$)
Other ThoughtsCorporate Culture

Apparent Female Officers or Directors: